期刊
CURRENT PSYCHIATRY REPORTS
卷 21, 期 8, 页码 -出版社
SPRINGER
DOI: 10.1007/s11920-019-1063-7
关键词
D-Serine; Keap1-Nrf2; Sodium benzoate; Soluble epoxide hydrolase; Sulforaphane; TrkB agonist
类别
资金
- Japan Society for the Promotion of Science (JSPS) KAKENHI [17H042431]
- Japan Agency for Medical Research and Development [JP19dm0107119]
Purpose of ReviewIn the past decade, there has been increasing interest in the potential benefit of early intervention in schizophrenia. Patients with schizophrenia show cognitive impairment for several years preceding the onset of psychosis. The author discusses the recent topics on prevention of schizophrenia.Recent FindingsPreclinical findings suggest that maternal immune activation (MIA) produces cognitive deficits as a prodromal symptom in juvenile offspring in rodents. Treatment with anti-inflammatory compounds, such as D-serine, 7,8-dihydroxyflavone (a TrkB agonist), sulforaphane (or its precursor glucoraphanin), and TPPU (1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea: a soluble epoxide hydrolase inhibitor), during adolescence might prevent the onset of behavioral abnormalities and parvalbumin immunoreactivity in the medial prefrontal cortex of adult offspring after MIA.SummaryBased on the role of inflammation and cognitive impairment in the prodromal state, early intervention using anti-inflammatory compounds (i.e., D-serine, sodium benzoate, TrkB agonist, Nrf2 agonist, soluble epoxide hydrolase inhibitor) may reduce the risk of subsequent transition to schizophrenia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据